MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00406-026-02361-4

Медицинская библиотека · European archives of psychiatry and clinical neuroscience · 2026

Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.

Martiadis Vassilis, Raffone Fabiola, Atripaldi Danilo, Pessina Enrico, Cattaneo Carlo Ignazio, Testa Serena, Iaccarino Concetta, d'Andrea Giacomo, Cavallotto Clara, Olivola Miriam, Dell'Osso Bernardo

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

Treatment-resistant depression (TRD) remains a highly burdensome clinical condition, and improvement in depressive severity does not necessarily imply parallel modification of maladaptive cognitive-affective processes such as rumination. We compared 6-month trajectories of depressive symptoms and depressive rumination across three active treatment conditions in routine clinical care: intranasal esketamine-based treatment without depression-specific metacognitive training (ESK), depression-specific metacognitive training without esketamine exposure (D-MCT), and combined esketamine plus D-MCT (D-MCT + ESK). Of 65 screened patients, 12 were excluded because of at least one absolute contraindication and 53 were enrolled (ESK n = 15, D-MCT n = 12, D-MCT + ESK n = 26). Seven participants did not complete the 6-month endpoint assessment (six in ESK and one in D-MCT + ESK), yielding a complete-case analysis set of 46 patients (ESK n = 9, D-MCT n = 12, D-MCT + ESK n = 25). Generalized estimating equations showed significant time effects and time-by-group interactions for both MADRS and RRS total scores. Endpoint ANCOVA models adjusting for baseline outcome value showed significant group effects at 6 months for MADRS (F(2,42) = 24.97, p<.001) and RRS (F(2,42) = 5.59, p=.007). Six-month MADRS response among completers was 3/9 (33.3%) in ESK, 4/12 (33.3%) in D-MCT, and 23/25 (92.0%) in D-MCT + ESK; corresponding intention-to-treat estimates using non-responder imputation were 3/15 (20.0%), 4/12 (33.3%), and 23/26 (88.5%). Concomitant treatment profiles showed marked imbalance in previous non-pharmacological treatment exposure, representing an important potential confounder. Findings support a cautious, hypothesis-generating interpretation because allocation was nonrandomized, assessment was open-label, the sample was modest, and baseline rumination was higher in the combined group.

Для цитирования: Martiadis Vassilis, Raffone Fabiola, Atripaldi Danilo, Pessina Enrico, Cattaneo Carlo Ignazio, Testa Serena, Iaccarino Concetta, d'Andrea Giacomo, Cavallotto Clara, Olivola Miriam, Dell'Osso Bernardo. Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.. European archives of psychiatry and clinical neuroscience. 2026. DOI: 10.1007/s00406-026-02361-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.